Hemp compounds show promise for managing blood sugar spikes

Researchers have identified three compounds derived from hemp seeds—Cannabisin A (CA), Cannabisin B (CB), and Cannabisin F (CF)—that show remarkable potential for managing diabetes and blood sugar control. Using both computational modeling and laboratory experiments, scientists found that CA and CF work similarly to acarbose (a common diabetes medication) by inhibiting an enzyme called α-glucosidase, which breaks down carbohydrates in the gut. This inhibition reduces how quickly glucose enters the bloodstream after eating. CB takes a different approach, showing weaker enzyme inhibition but uniquely enhancing the body's own incretin hormones (particularly GLP-1), which naturally regulate blood sugar.

In animal studies, both CA and CF effectively reduced dangerous blood sugar spikes after consuming sugar-heavy meals, matching the performance of the pharmaceutical drug acarbose. CB produced a different but promising effect—it delayed glucose absorption while triggering sustained, stronger insulin responses. Importantly, these hemp compounds appear to stay in the gut where they're needed rather than being absorbed into the bloodstream, suggesting minimal systemic side effects. The research also revealed that CB may cause fewer gastrointestinal side effects compared to acarbose and the other cannabisins, addressing a major complaint patients have with current diabetes medications.

These findings suggest that hemp seed-derived cannabisins represent a promising new class of gut-targeted diabetes treatments, potentially offering people with diabetes safer, more tolerable options for managing postprandial hyperglycemia (blood sugar spikes after meals). The dual mechanisms—enzyme inhibition and incretin enhancement—provide a multi-pronged approach that differs from conventional medications, opening new possibilities for natural compound-based diabetes management.